Japan’s Nihon Trim Gets U.S. FDA Clearance For Warfarin Diagnostic
This article was originally published in PharmAsia News
Executive SummaryU.S. FDA has cleared Japan's Nihon Trim subsidiary TrimGen to market its genotyping kit for warfarin anti-coagulant. The TrimGen kits develop genetic profiles of patients to test how they would react to warfarin as a treatment against heart attacks, strokes or blood clots without suffering severe bleeding. Nihon Trim already has four other types of kits on the U.S. market, but the 90-minute TrimGen kit is the first designed for use with Roche's LightCyclere Real-Time PCR System. Nihon Trim plans to team with another pharmaceutical firm to sell the kits, as early as this summer. (Click here for more - a subscription may be required
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.